| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. | Cancer | 2008 | 2.86 |
| 2 | XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms. | J Antimicrob Chemother | 2010 | 1.04 |
| 3 | XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity. | J Antimicrob Chemother | 2009 | 0.95 |